EI
ABOS icon

EAM Investors’s Acumen Pharmaceuticals ABOS Stock Holding History

EAM Investors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-208,571
Closed -$2.09M – 251
2022
Q3 		$2.09M Buy
+208,571
New +$1.2M 0.45% 83

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM Investors's ABOS Position: Q4 2022 in Review

EAM Investors sold out of Acumen Pharmaceuticals (ABOS) in Q4 2022, closing a stake of 208,571 shares — an estimated $2.09M sold.

EAM Investors first reported a position in ABOS in Q3 2022 and held it in 1 quarter. The position peaked at $2.09M in Q3 2022. 60 funds tracked by Wall St. Rank hold ABOS as of Q4 2022.

  • EAM Investors reported no remaining Acumen Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • EAM Investors sold 208,571 Acumen Pharmaceuticals shares in Q4 2022, an estimated $2.09M.
  • EAM Investors first reported a position in Acumen Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • EAM Investors's Acumen Pharmaceuticals position peaked at $2.09M in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2022.

Based on EAM Investors's 13F filing for Q4 2022, filed 14 Feb 2023.